Emerging Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Trends: Advancements In Cell And Gene Therapy Manufacturing Shaping the Future of the Industry

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Size Growth Forecast: What to Expect by 2025?
The market size of the cell and gene therapy contract development and manufacturing organization (CDMO) has seen a phenomenal increase in recent times. Surging from a value of $5.41 billion in 2024, it is projected to escalate to $6.94 billion in 2025 with a compound annual growth rate (CAGR) of 28.2%. Factors such as technological advancements, supportive regulatory structures, increased funding, the rising incidence of genetic disorders and a surge in strategic partnerships are attributable to this historic period growth.

How Will the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Size Evolve and Grow by 2029?
The market for cell and gene therapy contract development and manufacturing organization (CDMO) is projected to experience substantial expansion in the upcoming years. It is predicted to reach $18.54 billion in 2029, reflecting a compound annual growth rate (CAGR) of 27.8%. The anticipated growth in the subsequent period can be credited to advancements in therapeutic applications, regulatory developments, heightened investment, technological progress, and worldwide collaboration. During the forecast period, key trends will be the increasing demand for individualized therapies, the rise in automation and digitalization, widening of manufacturing capacities, introduction of new delivery systems, and an intensified emphasis on sustainability and environmental effect.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

What Drivers Are Propelling the Growth of Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Forward?
The escalating number of cancer incidences is poised to boost the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer is essentially a cluster of illnesses that exhibit uncontrolled growth and the spread of abnormal cells throughout the body. The increased cancer prevalence is due to factors such as ageing societies, changes in lifestyle, exposure to environmental risks, and better detection techniques. The role of cell and gene therapy contract development and manufacturing organization (CDMO) is to mitigate the prevalence of cancer by devising and producing innovative, precision treatments that augment efficacy and patient outcomes. For instance, as per Macmillan Cancer Support, a UK-based charity organization, the estimated population affected by cancer in the UK is anticipated to rise from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the escalating prevalence of cancer incidences bolsters the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

Which Emerging Trends Are Transforming the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market in 2025?
Major firms engaged in the cell and gene therapy Contract Development and Manufacturing Organization (CDMO) sector are concentrating on portfolio expansion through innovative solutions such as PluriMatrix technology. This proprietary system is designed specifically to enable mass production of cell-based products. It allows for 3D cell expansion on an industrial scale, delivering high output and consistent quality via a fully controlled, automated, and validated process. For instance, Pluri, an Israeli biotech company, unveiled PluriCDMO, a new business unit providing contract development and manufacturing services for cell therapy, in January 2024. With a 47,000-square-foot Good Manufacturing Practice (GMP) cell therapy production facility, this new unit provides a comprehensive service that spans from the initial preclinical phase to late-stage clinical trials and commercialization. It handles various areas, including process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as announced by the company. By utilizing the company's advanced PluriMatrix technology, it provides sophisticated cell therapy manufacturing services.

What Are the Key Segments in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
The cell and gene therapy contract development and manufacturing organization (CDMO) market covered in this report is segmented -

1) By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy
2) By Phase: Phase 1, Phase 2, Phase 3, Phase 4
3) By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications

Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy, TCR-T Cell Therapy, NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy, Progenitor Cell Therapy, Immune Cell Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

Who Are the Key Players Shaping the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market's Competitive Landscape?
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

What Geographic Markets Are Powering Growth in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.